)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Anavex Life Sciences
Anavex Life Sciences (AVXL) investor relations material
Anavex Life Sciences Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary9 Feb, 2026
Executive summary
Advanced clinical pipeline focused on oral blarcamesine for early Alzheimer's disease and other CNS disorders, with ongoing and completed clinical trials in Alzheimer's, Parkinson's, Rett syndrome, Fragile X syndrome, and schizophrenia.
Engaged with regulatory agencies in the US and Europe, including FDA Type C meeting and EMA re-examination request after initial CHMP negative opinion on blarcamesine.
Participation in ACCESS-AD, a major European initiative to accelerate adoption of innovative Alzheimer's diagnostics and therapeutics, with blarcamesine to be evaluated in a clinical prediction study.
Completed key clinical trials in Alzheimer's, Parkinson's, Rett syndrome, and schizophrenia, with positive safety and efficacy trends reported.
Multiple scientific presentations and publications planned, including new biomarker and genetic findings.
Financial highlights
Cash and cash equivalents were $131.7 million at December 31, 2025, up from $102.6 million at September 30, 2025, with no debt and a projected cash runway exceeding three years.
Research and development expenses decreased to $4.7 million from $10.4 million year-over-year; general and administrative expenses fell to $2.1 million from $3.1 million.
Net loss for the quarter was $5.7 million ($0.06 per share), improved from $12.1 million ($0.14 per share) in the prior year.
Cash used in operating activities was $7.1 million to $7.2 million for the quarter.
$36.3 million raised through equity financing in Q1 FY2026.
Outlook and guidance
Expectation to submit existing phase IIB/III data to FDA and continue regulatory engagement for blarcamesine.
EMA re-examination process for blarcamesine expected to last through the first half of the year, with a 60+60 day review period.
Plans to initiate or advance new clinical trials in Parkinson's disease, Rett syndrome, Fragile X syndrome, and schizophrenia-related disorders.
ACCESS-AD trial to serve as a confirmatory study for regulatory purposes.
Management expects continued negative cash flows from operations as all drug candidates remain in clinical development.
EMA reexamination: ADCS-ADL validity argument
FDA submission timeline for blarcamesine?
ACCESS-AD (AD-006) trial objectives?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Anavex Life Sciences earnings date
Q2 202612 May, 2026
Anavex Life Sciences
Next Anavex Life Sciences earnings date
Q2 202612 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. The company's lead drug candidate is 2-73 that has completed phase II clinical trial for the treatment of Alzheimer's disease. Its programs also includes ANAVEX 3-71, which is in pre-clinical testing for the treatment of amyotrophic lateral sclerosis disease; and ANAVEX 1-41, a pre-clinical stage small molecule compound for the treatment of epilepsy.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage